ASCO 2026: RLTs Generate Buzz Despite Commercial, Tolerability Hurdles

According to a report from Pharmaceutical Technology, radiopharmaceutical therapies (RLTs) were a hot topic at the American Society of Clinical Oncology (ASCO) 2026 meeting. Despite the buzz, experts noted that certain limitations must be addressed to facilitate their widespread use in cancer care.

Details

RLTs are treatments that use radioactive molecules to target specific receptors on cancer cells, delivering radiation directly to the tumor. At ASCO 2026, several companies, including Eli Lilly (LLY) and Bristol-Myers Squibb (BMY), presented new efficacy data. However, experts raised concerns about commercial challenges such as production costs and logistical complexities, as well as tolerability issues like renal toxicity and other side effects.

Context

These discussions come amid growing investor and corporate interest in RLTs. Eli Lilly recently acquired Point Biopharma, a specialist in this field, while Bristol-Myers Squibb has partnered to develop similar therapies. Still, the path to broad clinical adoption remains lengthy.

What This Means for Investors

While RLTs show promising potential, investors should monitor companies' ability to overcome commercial and regulatory hurdles. Focus on long-term clinical data and manufacturing plans will be key to assessing growth opportunities in this space.